Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Correlation between CD133 and EGFR Expression with Grading of Ovarian Carcinoma

View through CrossRef
BackgroundOvarian carcinoma account for 90% of all malignant ovarian tumors. Epidermal Growth Factor Receptor (EGFR), also known asErbB1/HER1, has an important role in tumor cell proliferation. CD133 is a marker for hematopoietic stem cell and it is involved in tumorcell proliferation, self renewal and cell differentiation. The objective to analyze the expression of CD 133 and EGFR in high grade andlow grade ovarian carcinoma, and to determine the correlation between the expression of CD133 and EGFR expression in ovariancarcinoma.MethodsThe study was conducted with observational and cross sectional method on paraffin blocks of patients diagnosed as ovariancarcinoma from 1 January until 31 December 2017 in Dr. Soetomo Hospital. Ovarian carcinoma was divided into 2 grade, low gradeand high grade. Immunohistochemistry for EGFR and CD133 was performed. Immuno-reactive Score (IRS) was applied to evaluatethe expression of EGFR and CD133. The difference expression of CD133 and EGFR in low grade and high grade ovarian carcinomawas analyzed with Mann-Whitney test. Correlation between CD133 with EGFR was analyzed with Spearman test.ResultsThere were significant difference in expression of CD133 (p=0.0001) and EGFR (p=0.0005) in high grade and low grade OvarianCarcinoma. There was significant positive correlation between CD133 and EGFR expression in Ovarian Carcinoma (p=0.035; r=0.37)ConclusionExpression of CD133 and EGFR were higher in high grade ovarian carcinoma. The higher expression of CD133 will increaseexpression of EGFR in ovarian carcinoma. Both markers may be used as prognostic factor.
Title: Correlation between CD133 and EGFR Expression with Grading of Ovarian Carcinoma
Description:
BackgroundOvarian carcinoma account for 90% of all malignant ovarian tumors.
Epidermal Growth Factor Receptor (EGFR), also known asErbB1/HER1, has an important role in tumor cell proliferation.
CD133 is a marker for hematopoietic stem cell and it is involved in tumorcell proliferation, self renewal and cell differentiation.
The objective to analyze the expression of CD 133 and EGFR in high grade andlow grade ovarian carcinoma, and to determine the correlation between the expression of CD133 and EGFR expression in ovariancarcinoma.
MethodsThe study was conducted with observational and cross sectional method on paraffin blocks of patients diagnosed as ovariancarcinoma from 1 January until 31 December 2017 in Dr.
Soetomo Hospital.
Ovarian carcinoma was divided into 2 grade, low gradeand high grade.
Immunohistochemistry for EGFR and CD133 was performed.
Immuno-reactive Score (IRS) was applied to evaluatethe expression of EGFR and CD133.
The difference expression of CD133 and EGFR in low grade and high grade ovarian carcinomawas analyzed with Mann-Whitney test.
Correlation between CD133 with EGFR was analyzed with Spearman test.
ResultsThere were significant difference in expression of CD133 (p=0.
0001) and EGFR (p=0.
0005) in high grade and low grade OvarianCarcinoma.
There was significant positive correlation between CD133 and EGFR expression in Ovarian Carcinoma (p=0.
035; r=0.
37)ConclusionExpression of CD133 and EGFR were higher in high grade ovarian carcinoma.
The higher expression of CD133 will increaseexpression of EGFR in ovarian carcinoma.
Both markers may be used as prognostic factor.

Related Results

Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Abstract LB177: Visualization and targeting of CD133+ cancer stem cells in MASLD-related hepatocellular carcinoma
Abstract LB177: Visualization and targeting of CD133+ cancer stem cells in MASLD-related hepatocellular carcinoma
Abstract Metabolic dysfunction-associated steatotic liver disease related hepatocellular carcinoma (MASLD-HCC) is an emerging malignancy. However, the identity and f...
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
8563 Background: There are limited reports on biomarker studies of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon...
CD133+ human pulmonary adenocarcinoma cells induce apoptosis of CD8+T cells by highly expressed galectin-3
CD133+ human pulmonary adenocarcinoma cells induce apoptosis of CD8+T cells by highly expressed galectin-3
Purpose To investigate the expression and function of Galectin-3 (Gal-3) in CD133+ pulmonary adenocarcinoma. Methods CD133+ pulmonary adenocarcinoma cells were separated by MACS fr...
Abstract 875: PAX8 protein detection in serum of patients with serous ovarian cancer
Abstract 875: PAX8 protein detection in serum of patients with serous ovarian cancer
Abstract Introduction: The paired-box (PAX) genes encode a family of transcription factors (TFs) with critical roles in the formation of tissues and organs during em...
Abstract 557: Noninvasive analysis of acquired resistance to EGFR-TKI
Abstract 557: Noninvasive analysis of acquired resistance to EGFR-TKI
Abstract BACKGROUND Epidermal growth factor receptor (EGFR) T790M mutation is associated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance i...
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract Epithelial ovarian cancer (EOC) accounts for 5% of all cancer deaths and is the fifth leading cause of cancer death in women in the United States. While the...

Back to Top